logo

For the Inventor, By the Inventor

Weesp, Netherlands

Gustaaf J M Van Scharrenburg

This inventor holds 17 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Solvay Pharmaceuticals, B.v., Duphar International Research Bv, Solvay Pharmaceuticals, Gmbh. Active years: 2004-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gustaaf J M Van Scharrenburg. Retrieved from https://idiyas.com/inventor/gustaaf-j-m-van-scharrenburg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17

% Patents Active = 23.5

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 50(Granted Patents)


Location History:

  • Weesp, NL (2004 - 2012)
  • Weep, NL (2010 - 2012)

Company Filing History:

goldMedal14 out of 67 
 
Solvay Pharmaceuticals, B.v.
 patents
silverMedal1 out of 169 
 
Duphar International Research Bv
 patents
bronzeMedal1 out of 77 
 
Solvay Pharmaceuticals, Gmbh
 patents
4. 1 out of 834,601 
Other
 patents

Years Active: 2004-2012

Loading Chart...
Areas of Expertise:
Dopamine Agonists
Piperazine Derivatives
Vaccine Adjuvants
Benzimidazolone
Quinazolinone
Transdermal Delivery
Prodrugs
Cytotoxicity
NADPH Quinone Oxido-Reductase
Glutathione-S-Transferase
Phenylpiperazines
17 patents (USPTO):Explore Patents
1. 8106056 - Combination preparations comprising bifeprunox and a dopamine agonist (2012-01-31),
2. 8101619 - [object Object] (2012-01-24),
3. 8067603 - Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors (2011-11-29),
4. 7915262 - Combination preparations comprising SLV308 and a dopamine agonist (2011-03-29),
5. 7851630 - Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors (2010-12-14),
6. 7786126 - Combination preparations comprising SLV308 and a dopamine agonist (2010-08-31),
7. 7750013 - N-oxides as prodrugs of piperazine and piperidine derivatives (2010-07-06),
8. 7678789 - [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular (2010-03-16),
9. 7596407 - Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds (2009-09-29),
10. 7297699 - Piperazine and piperidine compounds (2007-11-20),
11. 7244734 - [object Object] (2007-07-17),
12. 7202238 - [object Object] (2007-04-10),
13. 7094779 - Piperazine oxime dervatives having NK-1 receptor antagonistic activity (2006-08-22),
14. 6911448 - Piperazine and piperidine compounds (2005-06-28),
15. 6828325 - Phenylpiperazines (2004-12-07),

Title: Gustaaf J M Van Scharrenburg: Innovator in Pharmacological Compositions

Introduction

Gustaaf J M Van Scharrenburg is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmacology, holding a total of 17 patents. His work primarily focuses on innovative compositions for treating disorders related to dopaminergic function.

Latest Patents

One of his latest patents involves combination preparations comprising bifeprunox and a dopamine agonist. This invention relates to a composition containing bifeprunox or its N-oxide, or at least one pharmacologically acceptable salt thereof, along with L-DOPA or at least one pharmacologically acceptable salt thereof. This composition is intended for simultaneous, separate, or sequential use in treating disorders such as Parkinson's disease and restless leg syndrome. Another significant patent pertains to a group of novel phenylpiperazine derivatives that exhibit a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine-D receptors. This invention also covers the use of these compounds for manufacturing a medicament that provides beneficial effects.

Career Highlights

Throughout his career, Gustaaf has worked with various companies, including Solvay Pharmaceuticals. His expertise in pharmacological innovations has positioned him as a key figure in the development of new therapeutic solutions.

Collaborations

Gustaaf has collaborated with notable professionals in his field, including Andrew C McCreary and Roelof W Feenstra. These collaborations have further enhanced the impact of his inventions in the pharmaceutical industry.

Conclusion

Gustaaf J M Van Scharrenburg's contributions to pharmacology through his innovative patents demonstrate his commitment to advancing medical treatments. His work continues to influence the development of effective therapies for neurological disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…